1,552 Shares in Bio-Rad Laboratories, Inc. (NYSE:BIO) Bought by Lecap Asset Management Ltd.

Lecap Asset Management Ltd. purchased a new stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 1,552 shares of the medical research company's stock, valued at approximately $510,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. UMB Bank n.a. raised its stake in shares of Bio-Rad Laboratories by 140.6% during the third quarter. UMB Bank n.a. now owns 77 shares of the medical research company's stock worth $26,000 after buying an additional 45 shares during the last quarter. Gladius Capital Management LP bought a new position in Bio-Rad Laboratories during the third quarter worth about $32,000. Point72 Hong Kong Ltd acquired a new stake in Bio-Rad Laboratories during the third quarter worth about $55,000. Livforsakringsbolaget Skandia Omsesidigt grew its stake in Bio-Rad Laboratories by 281.7% during the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 271 shares of the medical research company's stock worth $91,000 after buying an additional 200 shares in the last quarter. Finally, Quarry LP grew its stake in Bio-Rad Laboratories by 38.1% during the third quarter. Quarry LP now owns 297 shares of the medical research company's stock worth $99,000 after buying an additional 82 shares in the last quarter. 65.24% of the stock is currently owned by institutional investors and hedge funds.

Bio-Rad Laboratories Price Performance

NYSE BIO traded down $2.62 on Wednesday, reaching $312.11. 231,563 shares of the company's stock traded hands, compared to its average volume of 162,474. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.14 and a quick ratio of 4.52. Bio-Rad Laboratories, Inc. has a 12 month low of $262.12 and a 12 month high of $387.99. The stock has a market cap of $8.74 billion, a PE ratio of -11.42 and a beta of 0.90. The stock has a 50-day simple moving average of $340.56 and a 200 day simple moving average of $336.91.

Analyst Ratings Changes

Several brokerages recently issued reports on BIO. Citigroup lifted their price target on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a "buy" rating in a report on Thursday, October 31st. StockNews.com upgraded shares of Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a research report on Friday, November 1st. Royal Bank of Canada restated an "outperform" rating and set a $481.00 price objective on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. Finally, Wells Fargo & Company reduced their target price on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an "equal weight" rating for the company in a research note on Wednesday. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $395.20.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.